Catalog No.
Product Name
Application
Product Information
Citations
-
PGA2 Analog
15-Deoxy-Δ12,14-prostaglandin A2 is a synthetic analog of prostaglandin A2 (PGA2) that primarily acts through the modulation of inflammatory responses. This compound exhibits significant biological activity by influencing various signaling pathways related to cell proliferation and apoptosis. It is commonly utilized in research applications focused on investigating the role of prostaglandins in inflammation, cardiovascular health, and tumor biology. -
Urinary Metabolite
PGDM (Prostaglandin D Metabolite) is the principal urinary metabolite of Prostaglandin D2, exhibiting reversible cyclization. This compound holds potential as a biomarker for the endogenous synthesis of PGD2 and is valuable in assessing the severity of acute allergic reactions. Its role in studying allergic responses makes PGDM significant for research in immunology and inflammation. -
Cervical Dilator
Meteneprost is a cervical dilator that enhances uterine contractility and facilitates the dilation of the cervical canal. This compound is utilized primarily in obstetric and gynecological research applications, particularly for inducing labor or preparing the cervix for medical procedures. Its ability to promote cervical changes makes it a valuable tool in studies focused on reproductive health and therapeutic interventions. -
Thromboxane Antagonist
L 640035 is a thromboxane antagonist that selectively inhibits the action of thromboxane A2, a potent vasoconstrictor and platelet aggregator. This compound demonstrates significant biological activity in modulating platelet aggregation and vascular tone, making it valuable for research in cardiovascular disorders and thrombotic diseases. It serves as a useful tool for studying the role of thromboxane in pathophysiological conditions and evaluating potential therapeutic interventions. -
Prostaglandin D Synthase Inhibitor
Pizuglanstat hydrate is a potent inhibitor of prostaglandin D synthase, exhibiting an IC50 of 76 nM for human hematopoietic prostaglandin D synthase. This compound effectively inhibits the synthesis of prostaglandin D2, making it relevant in research into inflammatory conditions. Pizuglanstat hydrate has demonstrated efficacy in improving experimental allergic rhinitis and offers potential applications in the study of muscle regenerative diseases, including muscular dystrophy. -
Prostaglandin Analog
17-trans Prostaglandin E3 is a prostaglandin analog that activates Nurr1-dependent transcriptional activity. This compound is instrumental in investigating biological processes related to Nurr1, including its implications in cancer and autoimmune diseases. Its properties make it valuable for research focused on these conditions and the underlying mechanisms of Nurr1 signaling. -
CRTH2 Antagonist
TASP0376377 is a highly potent and selective antagonist of the CRTH2 receptor, exhibiting an IC50 of 13 nM. This compound demonstrates strong binding affinity for CRTH2, with an IC50 of 19 nM. TASP0376377 is valuable for research applications focusing on inflammatory responses and immune modulation, particularly in studies related to asthma, allergy, and other CRTH2-related pathways. -
PGF2 Analog
15(R)-15-Methyl Prostaglandin F2α is a metabolically stable analog of PGF2α targeting prostaglandin receptors. This pharmacologically inactive prodrug is designed for activation through gastric acid, where acid-catalyzed epimerization converts it into the active 15(S)-isomer. The 15(S)-isomer effectively induces luteolysis in rhesus monkeys at approximately 12 mg per animal, making this compound valuable for research in reproductive biology and prostaglandin signaling pathways. -
Thromboxane A2 Receptor Antagonist
Vapiprost hydrochloride is a thromboxane A2 receptor antagonist that effectively inhibits platelet aggregation and ATP release induced by U-46619, collagen, or arachidonic acid (AA), with an IC50 of less than 2.1 × 10^-8 M. This compound serves as a valuable tool in studies focused on thromboxane signaling pathways and their implications in cardiovascular research. Its ability to modulate platelet activity makes it useful for investigating the mechanisms underlying thrombotic disorders and developing therapeutic interventions. -
TXA2/PGH2 Receptor Antagonist
LCB 2853 sodium is a potent antagonist of the thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor, demonstrating significant anti-aggregant and anti-vasospastic properties. This compound is useful for investigating cardiovascular diseases, including hypertension, by providing insights into the modulation of platelet aggregation and vascular response. Its role in cardiovascular research highlights its potential as a valuable tool in the study of related pathophysiological processes. -
Antithrombotic Agent
15(R)-PTA2, also known as 15(R)-Pinanethromboxane A2, functions as an antithrombotic agent primarily by inhibiting platelet aggregation. This compound effectively counteracts the constriction induced by stable prostaglandin endoperoxide analogs in feline coronary arteries while also stabilizing hepatic lysosomes. Additionally, 15(R)-PTA2 inhibits thromboxane synthase without affecting prostacyclin synthase, making it a valuable tool in cardiovascular research and the study of thrombotic disorders. -
PG analog
20-Ethyl prostaglandin E2 is a prostaglandin analog that primarily targets Nurr1, activating its transcriptional activity. This compound is useful in studies examining the regulation of gene expression and the role of Nurr1 in various biological processes, including neuroprotection and inflammation. Its application in research can provide insights into potential therapeutic strategies for conditions related to these pathways. -
Prostaglandin E Analogue
Flunoprost is a stabilized analogue of prostaglandin E, primarily targeting prostaglandin receptors. It exhibits significant biological activities, including the modulation of inflammatory responses and vascular function. Flunoprost is widely utilized in research applications related to cardiovascular studies, reproductive biology, and the exploration of inflammatory mediators. -
Prostaglandin I1 Analogue
Pimilprost is a prostaglandin I1 analogue that primarily targets the prostaglandin pathway. It exhibits significant antithrombotic activity and enhances intracellular cAMP levels. Pimilprost has demonstrated potential in promoting wound healing by stimulating angiogenesis and improving blood flow in diabetic models. This compound is valuable for research investigating metabolic and cardiovascular diseases, particularly in the context of diabetes. -
Isomer
5,6-trans-Travoprost is an isomer of Travoprost, serving as a critical experimental control in research. This compound acts as a selective, high-affinity agonist for the FP prostaglandin receptor, demonstrating significant ocular hypotensive effects. Primarily, 5,6-trans-Travoprost is utilized in studies related to glaucoma and ocular hypertension, facilitating investigations into therapeutic interventions for these conditions. -
IOP Lowering Agent
Prostaglandin F2α methyl ester is a lipophilic analog of Prostaglandin F2α, primarily functioning as an intraocular pressure (IOP) lowering agent. This compound effectively promotes aqueous humor outflow, leading to reduced intraocular pressure, which is critical in the management of glaucoma. Its unique solubility properties enhance its utility in ocular formulations and research applications related to eye health and disease. -
EP3 Receptor Antagonist
EP3 antagonist 6 is a selective EP3 receptor antagonist that demonstrates a potent inhibitory effect with an IC50 of 1.9 nM. This compound effectively blocks PGE2-induced uterine contractions in pregnant rat models, making it a valuable tool for exploring reproductive physiology and therapeutic interventions in uterine contractility. Its application in research can help elucidate the role of EP3 receptors in various biological processes. -
Prostaglandin Analog
15(R)-17-Phenyl trinor Prostaglandin F2α is a prostaglandin F (FP) analog that primarily targets FP receptors. It serves as an ocular hypotensive agent, although its structural modification results in reduced agonist activity at FP receptors compared to its active free acid counterpart, 17-Phenyl trinor Prostaglandin F2α. This compound is relevant in research applications focusing on glaucoma treatment and prostaglandin signaling pathways. -
TXA2R Antagonist
ICI 192605 is a potent antagonist of the thromboxane A2 receptor (TXA2R), a key regulator in cell signaling pathways involving prostaglandins. This compound effectively inhibits the contraction of isolated guinea pig trachea triggered by U-46619, demonstrating its potential in respiratory research. ICI 192605 is valuable for studies investigating the role of TXA2R in various physiological and pathological processes. -
Prostaglandin FP Receptor Agonist
Tafluprost ethyl ester is an agonist of the prostaglandin FP receptor, derived from Prostaglandin F2α (PGF2α). This compound demonstrates a myotic effect, making it useful in research related to ocular pressure reduction and glaucoma treatment. Its activity as a prostaglandin receptor modulator allows for exploration in various biological and pharmacological studies focused on intraocular effects and other prostaglandin-related pathways. -
Travoprost Derivate
13,14-epoxy Travoprost is a derivative of Travoprost, functioning primarily as a selective agonist for the prostaglandin F receptor. This compound exhibits significant ocular hypotensive activity, making it relevant for research into treatments for glaucoma and other intraocular pressure-related conditions. Its diastereomeric epoxide mixture provides a unique avenue for studying the pharmacological effects and mechanisms of action associated with prostaglandin analogs in ocular therapeutics. -
Prostaglandin Receptor Inhibitor
RS-61756-007 is a selective thromboxane receptor (TP) agonist that exhibits high affinity and activity specifically at the TP receptor. In vitro studies demonstrate that RS-61756-007 also shows agonistic effects at FP receptors, while remaining inactive against other receptor subtypes. The biological effects of RS-61756-007 can be effectively inhibited by the TP antagonist SQ 29,548. This compound is valuable for research aimed at understanding thromboxane signaling and its implications in various physiological and pathological processes. -
CRTH2 Antagonist
AM432 sodium is a selective antagonist of the CRTH2 receptor, also known as DP2. This compound exhibits high potency in human whole blood eosinophil assays, particularly under prolonged incubation conditions. Additionally, AM432 sodium has shown favorable pharmacokinetic profiles in canine and murine models of inflammatory diseases, making it a valuable tool for research in immunology and inflammatory pathways. -
Thromboxane Synthetase Inhibitor
Y-20811 sodium is a selective thromboxane synthetase inhibitor that exhibits potent and irreversible inhibition of thromboxane A2 synthesis. This compound is primarily utilized in cardiovascular research, particularly in studying thrombosis and its associated pathophysiological mechanisms. Its oral bioactivity makes it a valuable tool for investigating therapeutic interventions in thromboxane-related vascular disorders. -
PGF2α Analogues
17-Phenyl trinor prostaglandin F2α methyl amide is a potent analog of prostaglandin F2α (PGF2α) that selectively competes with native PGF2α for receptor binding. This compound exhibits key biological activities that enable its use in studies focused on reproductive biology and cardiovascular physiology. It serves as a valuable tool for investigating PGF2α-mediated signaling pathways and related therapeutic applications. -
Antithrombotic Agent
NP-184 is an innovative orally active antithrombotic agent that selectively inhibits thromboxane A2 (TXA2) synthase, demonstrating an IC50 of 4.3 μM. This compound exhibits notable antiplatelet and antithrombotic properties, making it valuable for research in thromboembolic diseases. Its targeted mechanism of action positions NP-184 as a significant tool in the study of cardiovascular disorders and related therapeutic developments. -
EP2 Agonist
(S)-Butaprost free acid is a potent and selective agonist of the EP2 receptor. This compound modulates various biological processes, including inflammation and smooth muscle relaxation. It is effectively utilized in research related to cardiovascular and respiratory diseases, as well as studies focused on reproductive biology. -
Prostacyclin Analogue
Naxaprostene is a selective prostacyclin analogue that primarily targets IP receptors, exhibiting partial agonistic activity. This compound effectively inhibits ADP-induced platelet aggregation, demonstrating significant antithrombotic properties. Naxaprostene has been shown to prevent thrombosis in models such as rabbit carotid artery, making it a valuable tool in cardiovascular research and studies focusing on platelet function and vascular health. -
Spasmodic
8-iso Prostaglandin E1 is a spasmodic agent that primarily targets pulmonary vascular smooth muscle. It exhibits significant vasodilatory properties, particularly in canine pulmonary veins, making it valuable for studies related to pulmonary hypertension and vascular dysfunction. This compound is useful in research focusing on the regulation of vascular tone and respiratory physiology. -
Prostacyclin Analogue
Ciprostene calcium is a prostacyclin analogue that primarily targets platelet activation pathways. It effectively inhibits adenosine diphosphate-induced platelet aggregation, making it a valuable tool in studies related to thromboembolic disorders. This compound is particularly useful in researching peripheral vascular disease and related cardiovascular conditions. -
EP4 Receptor Antagonist
BGC-20-1531 hydrochloride is a potent and selective antagonist of the prostanoid EP4 receptor, exhibiting a pKb of 7.6. This compound is primarily utilized in research related to migraine headaches, where modulation of the EP4 receptor may influence pain pathways and inflammatory processes. Its specificity makes it a valuable tool for investigating the roles of prostanoid signaling in various biological contexts. -
TP Agonist
AGN192093 is a selective thromboxane A2 receptor (TP) agonist, demonstrating an EC50 of 1.3 nM. This compound exhibits potent activity in modulating vascular responses and is useful for studies related to cardiovascular physiology and pathology. AGN192093 serves as a valuable tool for investigating the role of thromboxane A2 in various biological processes and disease models. -
Prostaglandin Receptor Antagonist
AL-3138 (11-Deoxy-16-fluoro PGF2α) functions as a prostaglandin receptor antagonist, specifically targeting the FP receptor. It effectively inhibits inositol phosphate production mediated by the FP prostaglandin receptor. This compound is valuable for research applications focused on prostaglandin signaling pathways and their implications in various physiological and pathological processes. -
Latanoprost Derivative
Latanoprost amide is a derivative of the F-prostaglandin (FP) receptor agonist, Latanoprost. It primarily acts on the FP receptor, demonstrating significant activity in reducing intraocular pressure. This compound is valuable in pharmacological research related to glaucoma and ocular hypertension, aiding in the development of new therapies targeting similar mechanisms. -
Prostaglandin Receptor
16-Phenoxy tetranor prostaglandin F2α is a metabolically stable analog that selectively binds to the FP receptor. This compound demonstrates significantly enhanced affinity for the FP receptor on ovine luteal cells, exhibiting a 440% increase compared to PGF2α. Its robust interaction profile makes it a valuable tool for investigating prostaglandin signaling pathways and their role in reproductive biology and endocrine functions. -
Thromboxane Inhibitor
BM567 is a potent thromboxane A2 receptor (TXR) antagonist and thromboxane A2 synthase (TXS) inhibitor, with IC50 values of 1.1 nM and 12 nM, respectively. This sulfonylurea compound demonstrates significant antithrombogenic activity, making it a valuable tool for studying thromboxane signaling pathways in various biological contexts. Its application extends to research on cardiovascular diseases and the role of thromboxane in platelet aggregation and vasoconstriction. -
PGI2 Agonist
FR-181877 is a selective PGI2 agonist that enhances prostacyclin signaling. It exhibits significant inhibitory activity on ADP-induced human platelet aggregation, with an IC50 value of 0.081 μM. This compound is valuable for research focusing on cardiovascular biology and hemostasis, offering insights into platelet function and potential therapeutic applications in thrombotic disorders. -
Prostaglandin Derivative
13(R),14(R)-epoxy Fluprostenol isopropyl ester is a Prostaglandin derivative that exhibits potent activity by acting on the FP receptors. This compound is primarily used in research to study its role in reproductive biology and vascular function. Its unique chemical structure allows for exploration in various pharmacological applications, particularly in the development of therapeutics targeting prostaglandin pathways. -
Thromboxane A2 Receptor Inhibitor
Samixogrel is a potent thromboxane A2 receptor inhibitor that modulates thromboxane synthesis. Its mechanism of action involves blocking the thromboxane A2 signaling pathway, which is crucial for platelet aggregation and vascular constriction. This compound is primarily utilized in research related to cardiovascular disease and thrombotic disorders, providing valuable insights into the role of thromboxane A2 in pathophysiological processes. -
Crth2 Antagonist
CRTh2 antagonist 3 is a potent antagonist of the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2). This compound enhances the activity of phosphoinositide-dependent kinase-1 (PDK1) towards a short peptide substrate, exhibiting an EC50 of 2 μM and a Kd of 8.4 μM. Its potential applications include research into cardiovascular inflammation and the modulation of Th2-mediated responses. -
Cervical Dilator
Meteneprost potassium is a cervical dilator that primarily acts by stimulating uterine contractions and facilitating the dilation of the cervical canal. This agent is utilized in obstetric applications, particularly for the induction of labor and cervical preparation prior to surgical procedures. Its efficacy in promoting cervical ripening makes it a valuable reagent in reproductive health research. -
EP2 Receptor Agonist
EP2 receptor agonist 2 (compound 18a) is a highly selective G protein-biased agonist of the EP2 receptor, demonstrating an EC50 of 13 nM for hEP2G protein activation and minimal interaction with the β-arrestin pathway (EC50 > 10000 nM). This compound exhibits remarkable selectivity for the EP2 receptor, with EC50 values greater than 10000 nM for hEP1, hEP3, hEP4, hIP, and hFP. It serves as a valuable tool for research in inflammation and pain pathways, facilitating studies on EP2 receptor signaling and its therapeutic potential. -
IP receptor Agonist
IP receptor agonist 1 is an orally active agonist of the I prostanoid receptor, exhibiting a potent IC50 of 0.15 μM for the inhibition of ADP-induced platelet aggregation in rabbit platelet-rich plasma. This compound is relevant for research applications focused on pulmonary arterial hypertension, offering insights into the modulation of platelet function and vascular health. -
PGF2α Analogue
Prostaglandin F2α ethyl amide is an analog of Prostaglandin F2α that functions primarily as a potent intraocular pressure (IOP) lowering agent. The N-ethyl amide modification enhances its efficacy compared to the parent compound, making it useful in research related to ocular health and glaucoma treatment. This compound is valuable for studies focused on the pharmacological modulation of IOP and the underlying mechanisms of action related to prostaglandin receptors. -
TP Agonist
8-iso-15-keto Prostaglandin F2α is a partial agonist targeting the Thromboxane receptor (TP). It demonstrates notable vasoconstrictive activity with a pD2 value of 5.8. Additionally, at elevated concentrations, this compound can induce mild relaxation effects in rat aorta rings, making it relevant for studies in vascular biology and related research applications. -
Prostacyclin Analogue
Nileprost is a prostacyclin analogue that functions as a mixed-type agonist for both PGI2 and PGE2 receptors. It demonstrates significant biological activity in promoting vasodilation and inhibiting platelet aggregation. Nileprost is primarily utilized in research involving acute myocardial ischemia, providing valuable insights into cardiovascular function and pathophysiology. -
DP/EP partial agonist
AL-6598 is a partial agonist of the prostaglandin DP and EP receptors. This compound is known to effectively reduce intraocular pressure, making it valuable for research related to glaucoma and ocular health. Investigations utilizing AL-6598 can provide insights into the mechanisms of intraocular pressure regulation and potential therapeutic strategies for glaucoma management. -
EP2/EP3 Receptors Agonist
11-Deoxy-16,16-dimethyl-PGE2 is an analog of Prostaglandin E2 that functions as an agonist of the EP2 and EP3 receptors. This compound exhibits protective effects against nephrotoxicity-induced damage in proximal renal tubular epithelial cells, primarily through its antioxidative properties. Its research applications include studies on renal protection, oxidative stress response, and receptor signaling pathways associated with kidney function. -
PGF2α Antagonist
Prostaglandin F2α dimethyl amide is an antagonist of Prostaglandin F2α, effectively inhibiting its biological activity. At a concentration of 3.2 μg/mL, it blocks up to 50% of PGF2α-induced contractions in the colon of gerbils (Meriones unguiculatus). This compound is valuable for research applications focused on gastrointestinal motility and prostaglandin signaling pathways. -
EP1 Receptor Antagonist
GW 848687X is a selective antagonist of the prostaglandin EP1 receptor, primarily involved in the modulation of inflammatory pain. This orally active compound demonstrates significant bioavailability, achieving 54% in rats and 53% in dogs. With a half-life of 2 hours, GW 848687X exhibits potential in both acute and chronic pain management research applications.
